MedTrace Logo

Bioavailability Study of Torsemide Tablets Under Fasting Conditions

NCT00653549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-06-17

No results posted yet for this study

Summary

To compare the single-dose bioavailability of Torsemide tablets with Demadex

Conditions

  • To Determine Bioequivalence Under Fasting Conditions

Interventions

DRUG

Torsemide

Tablets, 20 mg, single-dose

DRUG

Demadex

tablets, 20 mg, single-dose

Sponsors & Collaborators

  • Anapharm

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Masson · Anapharm

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2001-05-31
Completion
2001-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653549 on ClinicalTrials.gov